A5038965321- T-cell and Retrovirus Studies
- Vector-Borne Animal Diseases
- Animal Disease Management and Epidemiology
- Immune Cell Function and Interaction
- Galectins and Cancer Biology
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cutaneous lymphoproliferative disorders research
- Viral-associated cancers and disorders
- Hematopoietic Stem Cell Transplantation
- Cancer-related gene regulation
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
- Retinoids in leukemia and cellular processes
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Childhood Cancer Survivors' Quality of Life
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer survivorship and care
- Ubiquitin and proteasome pathways
- Viral Infections and Immunology Research
- Acute Myeloid Leukemia Research
- Glycosylation and Glycoproteins Research
- Immunotherapy and Immune Responses
- Mycobacterium research and diagnosis
Imamura Hospital
2016-2025
Kagoshima University
1994-2021
The Japanese Data Center for Hematopoietic Cell Transplantation
2007-2021
Toranomon Hospital
2016
National Hospital Organization
2012-2016
Kumamoto University Hospital
2016
Kagoshima Medical Center
2012
National Cancer Center Hospital East
2012
Sasebo City General Hospital
2007-2012
Nagasaki Medical Center
2007-2012
Adult T-cell leukemia-lymphoma (ATL) is usually resistant to conventional chemotherapies, and there are few other treatment options. Because CC chemokine receptor 4 (CCR4) expressed on tumor cells from most patients with ATL, KW-0761, a humanized anti-CCR4 monoclonal antibody, which markedly enhances antibody-dependent cellular cytotoxicity, was evaluated in the of relapsed ATL.A multicenter phase II study KW-0761 for relapsed, aggressive CCR4-positive ATL conducted evaluate efficacy,...
Adult T-cell leukemia-lymphoma (ATL) is a distinct peripheral T-lymphocytic malignancy associated with retrovirus designated human lymphotropic virus type I (HTLV-1). The diversity in clinical features and prognosis of patients this disease has led to its subclassification into the following four categories: acute, lymphoma, chronic, smoldering types. chronic subtypes are considered indolent usually managed watchful waiting until progression, analogous management some lymphoid leukemia (CLL)...
Our previous phase II trial for treating human T-lymphotropic virus type I-associated adult T-cell leukemia-lymphoma (ATLL) with vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP), ranimustine, (AMP), vindesine, etoposide, carboplatin, (VECP) showed promising results. To test the superiority of VCAP-AMP-VECP over biweekly (CHOP), we conducted a randomized controlled exclusively ATLL.Previously untreated patients aggressive ATLL were assigned to receive either six courses every...
KW-0761, a defucosylated humanized anti-CC chemokine receptor 4 (CCR4) antibody, exerts strong antibody-dependent cellular cytotoxic effect. This phase I study assessed the safety, pharmacokinetics, recommended II dose and efficacy of KW-0761 in patients with relapsed CCR4-positive adult T-cell leukemia-lymphoma (ATL) or peripheral lymphoma (PTCL).Sixteen received once week for weeks by intravenous infusion. Doses were escalated, starting at 0.01, 0.1, 0.5, finally 1.0 mg/kg 3 +...
Summary This multicentre, randomized, phase II study was conducted to examine whether the addition of mogamulizumab, a humanized anti‐ CC chemokine receptor 4 antibody, mLSG 15, dose‐intensified chemotherapy, further increases efficacy without compromising safety patients with newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma ( ATL ). Patients were assigned 1:1 receive 15 plus mogamulizumab or alone. The primary endpoint complete response rate (% CR ); secondary endpoints included...
Adult T-cell leukemia-lymphoma (ATL) is a distinct mature malignancy caused by chronic infection with human T-lymphotropic virus type 1 diverse clinical features and prognosis. ATL remains challenging disease as result of its features, multidrug resistance malignant cells, frequent large tumor burden, hypercalcemia, and/or opportunistic infection. In 2009, we published consensus report to define prognostic factors, subclassifications, treatment strategies, response criteria. The 2009 has...
Although global H3K27me3 reprogramming is a hallmark of cancer, no effective therapeutic strategy for H3K27me3-high malignancies harboring EZH2WT/WT has yet been established. We explore epigenome and transcriptome in EZH2WT/Mu aggressive lymphomas show that mutual interference compensatory function co-expressed EZH1 EZH2 rearrange their own genome-wide distribution, thereby establishing restricted chromatin gene expression signatures. Direct comparison leading compounds introduces potency...
Adult T-cell leukemia/lymphoma (ATL) is an aggressive non-Hodgkin lymphoma with poor prognosis and few treatment options for patients relapsed, recurrent, or refractory disease. We evaluated the efficacy safety of valemetostat, a potent enhancer zeste homolog 2 (EZH2) EZH1 inhibitor, in treating relapsed (R/R) ATL. This multicenter phase trial enrolled R/R ATL (acute, lymphoma, unfavorable chronic type). Patients received valemetostat 200 mg/day orally until progressive disease unacceptable...
This phase II trial was performed to evaluate the efficacy of a new granulocyte colony‐stimulating factor (G‐CSF)‐supported multi‐agent chemotherapy protocol, LSG15, for aggressive adult T‐cell leukaemia‐lymphoma (ATL). Ninety‐six previously untreated patients with ATL were enrolled and grouped as: acute type (58), lymphoma (28) unfavourable chronic (10). Therapy consisted seven cycles VCAP (vincristine, cyclophosphamide, doxorubicin prednisone), AMP (doxorubicin, ranimustine prednisone)...
Summary Adult T‐cell leukaemia/lymphoma (ATLL) is an aggressive neoplastic disease that usually exhibits a CD4 + CD25 phenotype. Regulatory T cells (Treg), which suppress effector function, are characterized by the co‐expression of and CD25. We analysed expression forkhead/winged helix transcription factor (FoxP3), specific marker important for function Treg, on ATLL from 17 patients (peripheral blood, n = 8; lymph node, 9). Real‐time polymerase chain reaction immunostaining detected FoxP3...
Abstract Purpose: Adult T-cell leukemia/lymphoma (ATLL) has a very poor prognosis. We have developed the humanized defucosylated anti–CC chemokine receptor 4 (CCR4) monoclonal antibody KW-0761 as next generation immunotherapeutic agent. The first aim of present study was to evaluate whether antitumor activity would likely be sufficient for therapeutic clinical application against ATLL. second fully elucidate mechanism antibody-dependent cellular cytotoxicity (ADCC) mediated by this antibody....
Purpose The prognosis of acute- and lymphoma-type adult T-cell leukemia/lymphoma (ATL) is poor, but there marked diversity in survival outcomes. aim this study was to develop a prognostic index (PI) for ATL (ATL-PI). Patients Methods In retrospective review, data from 807 patients newly diagnosed with between January 2000 May 2009 were evaluated. We randomly divided subjects into training (n = 404) validation 403) samples, developed PI using multivariable fractional polynomial model. Results...
Purpose Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is one important treatment option for patients with aggressive adult T-cell leukemia/lymphoma (ATLL). Mogamulizumab (anti-CCR4 monoclonal antibody; Mog) was recently approved as a ATLL in Japan. Major concerns exist about the possible adverse effects of pretransplantation Mog because depletes regulatory T cells several months. We assessed impact on clinical outcomes after allo-HSCT. Patients and Methods included 996...
Adult T cell leukaemia/lymphoma (ATL) is a human leukaemia virus type-I (HTLV-I)-infected malignancy with poor prognosis. We herein developed novel therapeutic vaccine designed to augment an HTLV-I Tax-specific cytotoxic lymphocyte (CTL) response that has been implicated in anti-ATL effects, and conducted pilot study investigate its safety efficacy. Three previously treated ATL patients, classified as intermediate- high-risk, were subcutaneously administered the vaccine, consisting of...